Early Parkinson Disease

Publication Date: November 16, 2021

Key Points

Key Points

  • The treatment options for the alleviation of motor symptoms in the early stages of Parkinson disease (PD) are based on the enhancement of dopaminergic tone with levodopa, monoamine oxidase inhibitors, dopamine agonists (DAs), or a combination thereof.
  • The choice of initial treatment is influenced by the potential for neuropsychiatric adverse effects associated with DAs and dyskinesia and motor fluctuations associated with levodopa.

Treatment

...atment...

...vs. DAs vs. MAO-B inhibitors...

...hould counsel patients with early PD o...

...with early PD who seek treatment for mot...

...prescribe DAs as the initial dopaminergic therapy...

...ld not prescribe DAs to patients with ear...


...cribing levodopa...

...uld initially prescribe immediate-rel...

...nts with early PD, clinicians should pre...

...cians should routinely monitor pat...

...ans should counsel patients taking...

...s should counsel patients that in...


...escribing...

...icians should inform the patient and caregiver (w...

...icians should screen patients for cognitive imp...

...cians should screen patients for the presence of...

...ians should involve caregivers in assessment...

...linicians may screen patients for the presenc...

...s should integrate patient prefere...

...ld prescribe the lowest dose of DA requi...


...ing and Discontinuing DAs...

...ld recommend tapering or discontinuat...

...e discontinued due to adverse effe...


...ing MAO-B inhibitor...

...s should counsel patients with early PD on...

...prescribe MAO-B inhibitors as the initial...


...edications for Parkinson DiseaseHaving trouble vi...